EUVIMEDEUVIMED entdecken
Multizentrische StudieKlinische Studie (Phase III)Randomisierte kontrollierte Studie

Bladder Adjuvant Radiotherapy: Phase III Multicenter Randomized Controlled Trial of Adjuvant Radiotherapy or Observation for Postcystectomy Muscle-Invasive Bladder Cancer

Vedang Murthy iD, Priyamvada Maitre iD, Mahendra Pal iD, Amandeep Arora, Reena Phurailatpam, Rakesh Sharma, Deleep Gudipudi iD, Senthil Rajappa, Lincoln Pujari, Bhavesh Bandekar, Deepa Joseph iD, Sadhana Kannan und 8 weitere

Journal of Clinical Oncology · 01.07.2026 · 44 (19) · 1812-1821

DOI: 10.1200/jco-25-02093 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Journal of Clinical Oncology, erschienen am 01.07.2026. Verfasst von Vedang Murthy und 19 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiation Oncology, Tata Memorial Centre, Homi Bhabha National Institute, Mumbai, India. Hauptthemen laut MEDLINE: Urinary Bladder Neoplasms, Cystectomy, Watchful Waiting. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 21 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE To report the primary analysis of a multicenter, phase III randomized trial of adjuvant radiotherapy (RT) after chemotherapy and radical cystectomy (RC) in patients with high-risk muscle-invasive bladder cancer (MIBC). METHODS Patients with nonmetastatic urothelial MIBC at high risk after RC (any one of: T3-4, N1-3, margin positive, ≤10 nodes dissected) were randomly assigned 1:1 to adjuvant RT or observation (Obs), stratified by nodal involvement (yes/no) and chemotherapy (neoadjuvant/adjuvant/none). Stoma-sparing IG-IMRT 50.4Gy in 28 fractions was prescribed to the cystectomy bed and pelvic nodes. The primary end point was 2-year locoregional recurrence–free survival (LRFS), and the secondary end points were disease-free survival (DFS), bladder cancer–specific survival (BCSS), and overall survival (OS). RESULTS From June 2016 to May 2024, 153 patients were randomly assigned (Obs = 76, RT = 77), with 62% and 41% of patients having pT3-T4 and pN+ stages, respectively. Over 90% of the patients received systemic chemotherapy (71% neoadjuvant and 20% adjuvant), and none received immunotherapy. After a median follow-up of 47 months, the 2-year LRFS was significantly higher with adjuvant RT versus observation (87.1% v 76.0%, hazard ratio [HR], 0.43 [95% CI, 0.20 to 0.96], P = .04). The DFS was 71.6% versus 58.7% (HR, 0.62 [95% CI, 0.36 to 1.05]), BCSS was 79.6% versus 65.0% (HR, 0.59 [95% CI, 0.33 to 1.10]), and OS was 70.4% versus 57.4% (HR, 0.78 [95% CI, 0.49 to 1.26]) for RT and Obs, respectively. CONCLUSION Adjuvant pelvic IMRT after radical cystectomy and perioperative chemotherapy suggests an improvement in locoregional control in patients with high risk urothelial MIBC with no additional severe toxicity.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Urinary Bladder NeoplasmsCystectomyWatchful WaitingHumansFemaleAgedRadiotherapy, AdjuvantMaleMiddle AgedNeoplasm InvasivenessDisease-Free SurvivalAged, 80 and overChemotherapy, Adjuvant

Autor:innen und Institutionen

  • Department of Radiation Oncology, Tata Memorial Centre, Homi Bhabha National Institute, Mumbai, India.
  • Department of Surgery, Tata Memorial Centre, Homi Bhabha National Institute, Mumbai, India.
  • Department of Medical Physics, Tata Memorial Centre, Homi Bhabha National Institute, Mumbai, India.
  • Basavatarakam Indo-American Cancer Hospital and Research Institute, Hyderabad, India.
  • Homi Bhabha Cancer Hospital & MPMMMC, Varanasi, India.
  • All India Institute of Medical Sciences, Rishikesh, India.

ORCID-Profile: Vedang Murthy, Priyamvada Maitre, Mahendra Pal, Deleep Gudipudi, Deepa Joseph, Rahul Krishnatry, Amit Joshi, Vanita Noronha, Kumar Prabhash, Ganesh Bakshi, Gagan Prakash

Zitieren

APA

Murthy, V., Maitre, P., Pal, M., Arora, A., Phurailatpam, R., Sharma, R., Gudipudi, D., Rajappa, S., Pujari, L., Bandekar, B., Joseph, D., Kannan, S., Krishnatry, R., Misra, A., Joshi, A., Noronha, V., Prabhash, K., Menon, S., Bakshi, G., & Prakash, G. (2026). Bladder Adjuvant Radiotherapy: Phase III Multicenter Randomized Controlled Trial of Adjuvant Radiotherapy or Observation for Postcystectomy Muscle-Invasive Bladder Cancer. Journal of Clinical Oncology, 44(19), 1812-1821. https://doi.org/10.1200/jco-25-02093

Vancouver

Murthy V, Maitre P, Pal M, Arora A, Phurailatpam R, Sharma R, et al. Bladder Adjuvant Radiotherapy: Phase III Multicenter Randomized Controlled Trial of Adjuvant Radiotherapy or Observation for Postcystectomy Muscle-Invasive Bladder Cancer. Journal of Clinical Oncology. 2026;44(19):1812-1821. doi:10.1200/jco-25-02093

BibTeX
@article{Murthy2026,
  author = {Murthy, Vedang and Maitre, Priyamvada and Pal, Mahendra and Arora, Amandeep and Phurailatpam, Reena and Sharma, Rakesh and Gudipudi, Deleep and Rajappa, Senthil and Pujari, Lincoln and Bandekar, Bhavesh and Joseph, Deepa and Kannan, Sadhana and Krishnatry, Rahul and Misra, Ankit and Joshi, Amit and Noronha, Vanita and Prabhash, Kumar and Menon, Santosh and Bakshi, Ganesh and Prakash, Gagan},
  title = {Bladder Adjuvant Radiotherapy: Phase III Multicenter Randomized Controlled Trial of Adjuvant Radiotherapy or Observation for Postcystectomy Muscle-Invasive Bladder Cancer},
  journal = {Journal of Clinical Oncology},
  year = {2026},
  volume = {44},
  number = {19},
  pages = {1812--1821},
  doi = {10.1200/jco-25-02093}
}
Kostenlos starten →